ABOS

ACUMEN PHARMACEUTICALS INC

ABOS·00509G209·US·Common Stock·Healthcare - Biotechnology-Activist

ABOS (ACUMEN PHARMACEUTICALS INC) is held by 52 institutional investors as of Q1 2026. Largest holders: RA CAPITAL MANAGEMENT, L.P. ($49.5M), Alyeska Investment Group, L.P. ($5.8M), FRANKLIN RESOURCES INC ($5.4M). Net institutional sentiment: Bullish.

52
Holders
(5 Elite)
$82.7M
Total Value
77% (48)
Consensus
37 buying - 11 selling
13F: Insider & Congress:
ABOSSmart Money Verdict
View all
Held by 52 funds
5 elite
Who's Trading
ActivistJBJames B. Murray Jr.5.0%Apr 7, 2026
ActivistRA Capital Management, L.P.RA Capital Management, L.P.29.5%Mar 17, 2026
InsiderMMMeisner Derek MSell $7KMar 6, 2026
InsiderMMMeisner Derek MSell $28KFeb 27, 2026
InsiderMMMeisner Derek MSell $8KJan 28, 2026
InsiderMMMeisner Derek MSell $45KJan 26, 2026
InsiderMMMeisner Derek MSell $11KJan 23, 2026
InsiderOJOConnell Daniel JosephSell $5KJan 22, 2026
InsiderZMZuga MattSell $3KJan 22, 2026
InsiderSESiemers EricSell $2KJan 22, 2026
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
21M(+40.6%)$49.5M0.5%-70.41%
55
Increased
2.5M(+161.3%)$5.8M0.0%-27.11%
44
Unchanged
2.3M$5.4M0.0%-34.55%
0
New
1.5M$3.6M0.0%-20.54%
37
Decreased
1.2M(-42.9%)$2.7M0.0%+50.44%
0
Increased
968,940(+33.6%)$2.3M0.0%-26.21%
33
Unchanged
859,110$2M0.0%+7.28%
0
Increased
659,675(+12.9%)$1.6M0.0%-14.17%
29
Increased
601,476(+61.2%)$1.4M0.0%+4.69%
37
Increased
530,812(+270.6%)$1.3M0.0%-21.17%
41
Increased
473,946(+12.0%)$1.1M0.0%+26.31%
28
Increased
416,238(+1.5%)$982,7550.0%-29.98%
25
Increased
320,216(+33.3%)$755,7100.0%+24.72%
32
Increased
206,683(+75.4%)$487,7720.0%+15.76%
36
New
199,226$470,1730.0%-20.54%
33
Increased
192,889(+822.6%)$455,2180.0%-16.98%
39
Increased
178,326(+5.2%)$420,8490.0%+43.94%
17
Increased
151,728(+51.5%)$358,0780.0%-8.24%
22
Decreased
144,584(-13.4%)$341,2190.0%+12.52%
0
Increased
120,388(+150.9%)$284,1160.0%-7.25%
38

Showing 1-20 of 56

1 / 3

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used